• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES SAPIEN 3 TRANSCATHETER HEART VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES SAPIEN 3 TRANSCATHETER HEART VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED Back to Search Results
Model Number 9600TFX29
Device Problem Migration or Expulsion of Device (1395)
Patient Problem Insufficient Information (4580)
Event Date 02/01/2023
Event Type  Injury  
Event Description
As reported, it was a case of a 29mm sapien 3 transcatheter heart valve, in aortic position by left subclavian approach.During procedure, alignment difficulties were experienced.Once the valve was aligned, it was noted that the balloon was distally advanced and was re-aligned twice.During valve deployment, the balloon started filling distally.The valve was partially deployed distally when the valve jumped up from the annulus towards aorta.The delivery system was unable to be advance in order to reposition the valve and finalize the deployment.Therefore, it was decided to retrieve the valve to the left subclavian.The valve was removed surgically and a surgical valve was implanted.Surgery was successfully completed.There was no damage and no balloon leak during inflation were noted.
 
Manufacturer Narrative
The implant site characteristic is unknown.The investigation is ongoing.
 
Manufacturer Narrative
A supplemental mdr is being submitted for correction information.The following sections of this report have been updated: corrected information to h.6 impact code.The investigation is ongoing.
 
Manufacturer Narrative
A supplemental mdr is being submitted for correction and additional information.The following sections of this report have been updated: corrected investigation conclusions and investigation findings.Added new information to h.6 type of investigation.The device was not returned to edwards lifesciences for evaluation.Without the device returned for evaluation, visual inspection, functional testing and dimensional analysis were unable to be completed.Imagery was not provided for review.A review of the risk management documentation was performed, and no evidence of product non-conformances or labeling/ifu inadequacies were identified in the evaluation.The complaint was unable to be confirmed as no imagery/medical report was provided for evaluation.The reported event does not allege a malfunction that could be related to an edwards manufacturing deficiency.A review of ifu/training materials revealed no deficiencies.As reported, ''during procedure, alignment difficulties were experienced.Once the valve was aligned, it was positioned for deployment and the pusher was retrieved.Then, it was noticed that the balloon was distally advanced, it was needed re-align twice.When the deployment of the valve started, the balloon started filling distally.The valve, mounted on the balloon and partially deployed distally, jumped up from the annulus towards aorta.''.Per the instructions for use (ifu), valve embolization is a known potential complication associated with the transcatheter aortic valve replacement (tavr) procedure.In this case, the distal of inflation balloon was first inflated leading to valve embolized into aorta, which was indicating the valve was not align within the valve alignment markers or too proximal of inflation balloon prior to valve deployment.Per training manual, ''the thv is exactly between the valve alignment markers with no gap or overlap''.As such available, information suggests that procedural factors (improper valve alignment prior deployment) may have contributed to the complaint event.Complaint histories for all reported events are reviewed against trending control limits monthly, and any excursions above the control limits are assessed and documented as part of this monthly review.No ifu/labeling/training manual inadequacies were identified.Therefore, no corrective or preventative action nor product risk assessment is required at this time.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SAPIEN 3 TRANSCATHETER HEART VALVE
Type of Device
AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED
Manufacturer (Section D)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer Contact
renee van dorne
1 edwards way
irvine, CA 92614
9492506385
MDR Report Key16427665
MDR Text Key310065560
Report Number2015691-2023-11006
Device Sequence Number1
Product Code NPT
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P140031
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 03/30/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/23/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number9600TFX29
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received03/30/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured08/05/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-